|
Aug 27
|
InflaRx Announces Participation in September Investor Events
|
|
Jul 30
|
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
|
|
Jun 24
|
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
|
|
Jun 24
|
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
|
|
May 8
|
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 30
|
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
|
|
Apr 24
|
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
|
|
Mar 21
|
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
|
|
Mar 21
|
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
|
|
Mar 19
|
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
|
|
Mar 6
|
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
|
|
Dec 1
|
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
|
|
Nov 28
|
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)
|
|
Aug 10
|
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
|
|
Apr 7
|
Why InflaRx Stock Skyrocketed This Week
|
|
Apr 5
|
Why Shares of InflaRx Are Soaring Wednesday
|
|
Apr 5
|
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
|
|
Apr 4
|
UPDATE 1-InflaRx COVID injection gets US FDA's emergency-use authorization
|
|
Apr 4
|
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
|